Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy

1 October 1990

journal article
research article
Published by Wolters Kluwer Health in AIDS

Vol. 4 (10) , 1019-1022
https://doi.org/10.1097/00002030-199010000-00012

Abstract

Eflornithine (DFMO) was used to treat 31 AIDS patients with confirmed Pneumocystis carinii pneumonia who had clinically failed treatment with pentamidine, sulphamethoxazole-trimethoprim or both agents as their first-line therapy. Twenty-one of 31 (68%) responded to second-line treatment with 400 mg/kg per day of eflornithine. Five patients discontinued treatment because of bone marrow toxicity. Eflornithine appears to be a useful salvage therapy in patients failing first-line treatments.

Keywords

DRUG THERAPY

This publication has 6 references indexed in Scilit:

Prognostic Factors and Life Expectancy of Patients with Acquired Immunodeficiency Syndrome andPneumocystis cariniiPneumonia
American Review of Respiratory Disease, 1987
AEROSOLISED PENTAMIDINE AS SOLE THERAPY FOR PNEUMOCYSTIS CARINII PNEUMONIA IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME
The Lancet, 1987
Inhibition of Polyamine Biosynthesis by α-Difluoromethylornithine in African Trypanosomes and Pneumocystis carinii as a Basis of Chemotherapy: Biochemical and Clinical Aspects
The American Journal of Tropical Medicine and Hygiene, 1986
Dapsone-Trimethoprim for Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency Syndrome
Annals of Internal Medicine, 1986
Trimethoprim-Sulfamethoxazole or Pentamidine forPneumocystis cariniiPneumonia in the Acquired Immunodeficiency Syndrome
Annals of Internal Medicine, 1986
Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro
Antimicrobial Agents and Chemotherapy, 1985